Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 25. David Risinger ...

CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...

The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors.

In July, the Food and Drug Administration (FDA) approved the first blood test to use as primary screening for people at average risk for colon cancer. Called Shield, the test looks for the presence of ...

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

Venezuela criticises Brazil's decision to veto its admission to the Brics group of emerging economies. Three Americans were arrested, with Venezuela accusing them of working with US spy agencies ...

Some two-and-a-half years after buying the Novo Holdings portfolio company ReViral and its respiratory syncytial virus (RSV) candidate sisunatovir in a deal worth up to $525 million, US pharma giant ...

This week on Pipeline Moves, we kick off by looking at Pfizer’s topline data from a Phase II trial of ponsegromab on cancer cachexia. Meanwhile, IMPACT Therapeutics senaparib has seen its phase ...

The following is a summary of “Ponsegromab for the Treatment of Cancer Cachexia,” published in the September 2024 issue of Emergency Medicine by Groarke et al. Cachexia, a common cancer complication, ...